2024年10月29日，渤健（“Biogen”）和Neomorph宣布开展研究合作，以发现和开发用于治疗阿尔茨海默病、罕见神经系统疾病和免疫疾病的多个分子胶降解剂。 根据协议条款，Neomorph 将获得预付款，并有资格在合作各个阶段时获得包括临床前、临床、监管、商业和 ...

SAN DIEGO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Neomorph, Inc., a biotechnology company pioneering molecular glue degraders to address previously undruggable proteins, today announced the first patient ...

Please provide your email address to receive an email when new articles are posted on . Biogen Inc. and Neomorph Inc. have announced a partnership geared toward research and development of molecular ...

Neomorph是一家美国蛋白质降解剂研发商，公司正在建立一个蛋白质降解实体，专注于“分子胶”降解剂。靶向蛋白质降解为在包括肿瘤学在内的各种疾病领域开发新型疗法提供了机会。近日，Neomorph宣布完成了1亿美元的B轮融资。本轮融资由Deerfield Management领投 ...

SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- Neomorph, Inc., a biotechnology company advancing a new class of molecular glue degraders to target historically undruggable proteins, today announced the ...

The Nature Index tracks primary research articles from 145 natural-science and health-science journals, chosen based on reputation by an independent group of researchers. The Nature Index provides ...

SAN DIEGO, Feb. 03, 2026 (GLOBE NEWSWIRE) — Neomorph, Inc., a biotechnology company pioneering molecular glue degraders to address previously undruggable proteins, today announced the first patient ...

San Diego startup Neomorph on Monday announced a new $100 million investment for its molecular glue that tricks cancer cells into self-destructing. Even as it awaits results from its first clinical ...